pirarubicin has been researched along with Vaginal-Neoplasms* in 2 studies
2 other study(ies) available for pirarubicin and Vaginal-Neoplasms
Article | Year |
---|---|
Neoadjuvant Intraarterial Chemotherapy for Treatment of Malignant Vaginal Tumors in Children: A Single-Center Experience.
Six patients (aged 3-36 mo) with vaginal tumors (rhabdomyosarcoma and endodermal sinus tumor [EST]; n = 3 each) received intraarterial chemotherapy (IAC) and intravenous chemotherapy. Patients underwent internal iliac artery infusion with cisplatin, pirarubicin, and vindesine. Intravenous chemotherapy with vindesine, ifosfamide, and etoposide was administered after 3 weeks. Vaginal tumors disappeared in all patients after 2 or 3 cycles of alternating therapy. Two patients underwent resection of pelvic metastases. Intravenous consolidation chemotherapy was applied. Four patients were disease-free at a median follow-up of 5.8 years. One patient had pelvic recurrence treated with "salvage" therapy with IAC and surgery and was disease-free for 2.5 years. Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Child, Preschool; China; Cisplatin; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Endodermal Sinus Tumor; Etoposide; Female; Humans; Ifosfamide; Iliac Artery; Infant; Infusions, Intra-Arterial; Infusions, Intravenous; Metastasectomy; Neoadjuvant Therapy; Pelvic Neoplasms; Retrospective Studies; Rhabdomyosarcoma, Embryonal; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; Vaginal Neoplasms; Vindesine | 2016 |
[Phase II study of 4'-O-tetrahydropyranyl-adriamycin (THP-ADM) in patients with gynecological cancer].
We conducted a joint phase II study in 76 patients with gynecological cancer (42 patients with ovarian cancer, 22 patients with cervical cancer, 10 patients with endometrial cancer and 2 patients with vaginal cancer). The response rate was 25.0% in the patients with ovarian cancer, 13.3% in those with cervical cancer, and 28.6% in those with endometrial cancer. The overall response rate was 23.1%. When the patients were classified according to dose schedules, the highest response rate was obtained in the group administered THP-ADM at a dose of 60 mg per body by single i.v. injection at 3-week intervals. Such side effects as myelosuppression and gastrointestinal disturbances were observed, but alopecia, a marked side-effect of ADM administration, was mild, and no cardiac toxicity was seen in any of the patients. Topics: Adult; Aged; Doxorubicin; Drug Administration Schedule; Drug Evaluation; Female; Genital Neoplasms, Female; Humans; Middle Aged; Ovarian Neoplasms; Uterine Cervical Neoplasms; Uterine Neoplasms; Vaginal Neoplasms | 1985 |